Literature DB >> 27959577

Hyperosmotic environment blunts effectivity of ischemic preconditioning against ischemia-reperfusion injury and improves ischemic tolerance in non-preconditioned isolated rat hearts.

M Zálešák1, P BlaŽíček, D Pancza, I Gablovský, V Štrbák, T Ravingerová.   

Abstract

Several studies have shown that diabetes mellitus modulates heart resistance to ischemia and abrogates effectivity of cardioprotective interventions, such as ischemic preconditioning (IP). The aim of this study was to evaluate whether the effect of hyperglycemic conditions on the severity of ischemia-reperfusion (I/R) injury in preconditioned and non-preconditioned hearts (controls, C) is related to changes in osmotic activity of glucose. Experiments were performed in isolated rat hearts perfused according to Langendorff exposed to 30-min coronary occlusion/120-min reperfusion. IP was induced by two cycles of 5-min coronary occlusion/5-min reperfusion, prior to the long-term I/R. Hyperosmotic (HO) state induced by an addition of mannitol (11 mmol/l) to a standard Krebs-Henseleit perfusion medium significantly decreased the size of infarction and also suppressed a release of heart fatty acid binding protein (h-FABP - biomarker of cell injury) from the non-IP hearts nearly to 50 %, in comparison with normoosmotic (NO) mannitol-free perfusion. However, IP in HO conditions significantly increased the size of infarction and tended to elevate the release of h-FABP to the effluent from the heart. The results indicate that HO environment plays a cardioprotective role in the ischemic myocardium. On the other hand, increased osmolarity, similar to that in the hyperglycemic conditions, may play a pivotal role in a failure of IP to induce cardioprotection in the diabetic myocardium.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27959577     DOI: 10.33549/physiolres.933362

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  7 in total

Review 1.  Diabetes-Related Cardiac Dysfunction.

Authors:  Lamario J Williams; Brenna G Nye; Adam R Wende
Journal:  Endocrinol Metab (Seoul)       Date:  2017-06

2.  Effects of hypoglycemia on myocardial susceptibility to ischemia-reperfusion injury and preconditioning in hearts from rats with and without type 2 diabetes.

Authors:  Kim B Pælestik; Nichlas R Jespersen; Rebekka V Jensen; Jacob Johnsen; Hans Erik Bøtker; Steen B Kristiansen
Journal:  Cardiovasc Diabetol       Date:  2017-11-09       Impact factor: 9.951

3.  High glucose promotes hepatic fibrosis via miR‑32/MTA3‑mediated epithelial‑to‑mesenchymal transition.

Authors:  Qiang Li; Zhange Li; Yuan Lin; Hui Che; Yingying Hu; Xujuan Kang; Ying Zhang; Lihong Wang; Yong Zhang
Journal:  Mol Med Rep       Date:  2019-02-25       Impact factor: 3.423

4.  Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes.

Authors:  Steen Buus Kristiansen; Kim Bolther Pælestik; Jacob Johnsen; Nichlas Riise Jespersen; Kasper Pryds; Marie Vognstoft Hjortbak; Rebekka Vibjerg Jensen; Hans Erik Bøtker
Journal:  Cardiovasc Diabetol       Date:  2019-05-31       Impact factor: 9.951

5.  Cardioprotective Properties of Mannitol-Involvement of Mitochondrial Potassium Channels.

Authors:  Katharina Feige; Janine Rubbert; Annika Raupach; Martin Stroethoff; André Heinen; Markus W Hollmann; Ragnar Huhn; Carolin Torregroza
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

6.  Mediation of the Cardioprotective Effects of Mannitol Discovered, with Refutation of Common Protein Kinases.

Authors:  Carolin Torregroza; Chiara O Glashoerster; Katharina Feige; Martin Stroethoff; Annika Raupach; André Heinen; Markus W Hollmann; Ragnar Huhn
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

7.  Influence of Hyperglycemia on Dexmedetomidine-Induced Cardioprotection in the Isolated Perfused Rat Heart.

Authors:  Carolin Torregroza; Katharina Feige; Laura Schneider; Sebastian Bunte; Martin Stroethoff; André Heinen; Markus W Hollmann; Ragnar Huhn; Annika Raupach
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.